Brief: 3D Medicines Says FDA Approval For Global Phase III Trial
30/10/2023 01:07
Oct 30 (Reuters) - 3D Medicines Inc 1244.HK :
* FDA APPROVAL FOR GLOBAL PHASE III TRIAL FOR TREATMENT OF
FIRST
LINE MISMATCH REPAIR PROFICIENT ADVANCED OR RECURRENT
ENDOMETRIAL CANCER
Further company coverage: 1244.HK
Recent news on 3D Medicines
See all newsBrief: 3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
Brief: 3D Medicines Inc Says Zhang Jing Resigns As CFO
Brief: 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted
Brief: 3D Medicines Says Envafoimab Granted Orphan Drug Designation
Brief: 3D Medicines Inc Enters Strategic Agreement With Catug Biotechnology